Portal de investigación
A single arm, open-label Phase 3b study to describe the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagnosed with IDH1m acute myeloid leukemia (AML)ineligible for intensive induction chemotherapy.
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
SERVIER AFFAIRES MEDICALES
Cita
A single arm, open-label Phase 3b study to describe the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagnosed with IDH1m acute myeloid leukemia (AML)ineligible for intensive induction chemotherapy. (DIM-95031-006). SERVIER AFFAIRES MEDICALES. 2023IP:REBECA RODRÍGUEZ VEIGA,BLANCA BOLUDA PASCUAL.